Literature DB >> 21422203

Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumonia.

G L Drusano1, B Vanscoy, W Liu, S Fikes, D Brown, A Louie.   

Abstract

Outcomes for patients with dense bacterial burdens, such as ventilator-associated pneumonia (VAP) patients, are often critically influenced by the adequacy of antimicrobial chemotherapy and by the response of the immune system, particularly the granulocytes. Little information is available about the quantitation of kill of organisms over time by granulocytes. In this investigation, we examined the impact of the baseline bacterial burden on the ability of granulocytes alone (without chemotherapy) to keep the number of organisms in check or to kill them over a 24-h period. Pseudomonas aeruginosa ATCC 27853 was the study organism, and we employed a murine pneumonia model (granulocyte replete) for the study. We found that the ability of the immune system to kill P. aeruginosa was saturable. The burden at which the system was half saturated was 2.15 × 10⁶ ± 2.66 × 10⁶ CFU/g. Burdens greater than 10⁷ CFU/g demonstrated net growth over 24 h. These findings suggest the need for aggressive chemotherapy early in the treatment of VAP to keep the burden from saturating the granulocytes. This should optimize the outcome for these seriously infected patients.

Entities:  

Mesh:

Year:  2011        PMID: 21422203      PMCID: PMC3101416          DOI: 10.1128/AAC.01687-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation.

Authors:  G L Drusano; S L Preston; M H Gotfried; L H Danziger; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.

Authors:  Arnold Louie; Caroline Grasso; Nadzeya Bahniuk; Brian Van Scoy; David L Brown; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

3.  Inadequate treatment of ventilator-associated pneumonia: risk factors and impact on outcomes.

Authors:  P J Z Teixeira; R Seligman; F T Hertz; D B Cruz; J M G Fachel
Journal:  J Hosp Infect       Date:  2007-03-12       Impact factor: 3.926

4.  Efficacy of bilateral bronchoalveolar lavage for diagnosis of ventilator-associated pneumonia.

Authors:  Colleen R Zaccard; Ronald F Schell; Carol A Spiegel
Journal:  J Clin Microbiol       Date:  2009-07-15       Impact factor: 5.948

5.  Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.

Authors:  Thomas P Lodise; Mark Gotfried; Steven Barriere; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191

6.  Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model.

Authors:  G L Drusano; Christine Fregeau; Weiguo Liu; D L Brown; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

7.  Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia.

Authors:  F Scaglione; S Esposito; S Leone; V Lucini; M Pannacci; L Ma; G L Drusano
Journal:  Eur Respir J       Date:  2009-02-12       Impact factor: 16.671

8.  The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.

Authors:  G L Drusano; Nicole Sgambati; Adam Eichas; David L Brown; Robert Kulawy; Arnold Louie
Journal:  MBio       Date:  2010-08-10       Impact factor: 7.867

9.  Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia.

Authors:  Olivier Leroy; Agnès Meybeck; Thibaud d'Escrivan; Patrick Devos; Eric Kipnis; Hugues Georges
Journal:  Intensive Care Med       Date:  2003-09-12       Impact factor: 17.440

10.  Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets.

Authors:  Arnold Louie; Christine Fregeau; Weiguo Liu; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

  10 in total
  25 in total

1.  Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.

Authors:  Arnold Louie; Weiguo Liu; Michael VanGuilder; Michael N Neely; Alan Schumitzky; Roger Jelliffe; Steven Fikes; Stephanie Kurhanewicz; Nichole Robbins; David Brown; Dodge Baluya; George L Drusano
Journal:  J Infect Dis       Date:  2014-10-31       Impact factor: 5.226

Review 2.  Innate immune responses to Pseudomonas aeruginosa infection.

Authors:  Elise G Lavoie; Tamding Wangdi; Barbara I Kazmierczak
Journal:  Microbes Infect       Date:  2011-08-02       Impact factor: 2.700

Review 3.  Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.

Authors:  G L Drusano; Arnold Louie; Alasdair MacGowan; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

4.  Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model.

Authors:  George Louis Drusano; Weiguo Liu; Steven Fikes; Ryan Cirz; Nichole Robbins; Stephanie Kurhanewicz; Jaime Rodriquez; David Brown; Dodge Baluya; Arnold Louie
Journal:  J Infect Dis       Date:  2014-04-22       Impact factor: 5.226

Review 5.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

Review 6.  The immune response and antibacterial therapy.

Authors:  Olachi Anuforom; Graham R Wallace; Laura V Piddock
Journal:  Med Microbiol Immunol       Date:  2014-09-05       Impact factor: 3.402

7.  Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets.

Authors:  G L Drusano; T P Lodise; D Melnick; W Liu; A Oliver; A Mena; B VanScoy; A Louie
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

8.  Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal flora.

Authors:  Maleck V Vasseur; Michel Laurentie; Jean-Guy Rolland; Agnès Perrin-Guyomard; Jérôme Henri; Aude A Ferran; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

9.  Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design.

Authors:  Cornelia B Landersdorfer; Neang S Ly; Hongmei Xu; Brian T Tsuji; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

10.  Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance.

Authors:  Soon-Ee Cheah; Jian Li; Brian T Tsuji; Alan Forrest; Jürgen B Bulitta; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.